GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » 5-Year ROIIC %

KOD (Kodiak Sciences) 5-Year ROIIC % : -126.68% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Kodiak Sciences's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -126.68%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Kodiak Sciences's 5-Year ROIIC % or its related term are showing as below:

KOD's 5-Year ROIIC % is ranked worse than
72.35% of 1302 companies
in the Biotechnology industry
Industry Median: -22.27 vs KOD: -126.68

Kodiak Sciences 5-Year ROIIC % Historical Data

The historical data trend for Kodiak Sciences's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences 5-Year ROIIC % Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial - - -145.85 -167.21 -126.68

Kodiak Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -126.68 - - -

Competitive Comparison of Kodiak Sciences's 5-Year ROIIC %

For the Biotechnology subindustry, Kodiak Sciences's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kodiak Sciences's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's 5-Year ROIIC % falls into.



Kodiak Sciences 5-Year ROIIC % Calculation

Kodiak Sciences's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -277.321 (Dec. 2023) - -26.374 (Dec. 2018) )/( 199.833 (Dec. 2023) - 1.74 (Dec. 2018) )
=-250.947/198.093
=-126.68%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Kodiak Sciences  (NAS:KOD) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Kodiak Sciences 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kodiak Sciences Business Description

Traded in Other Exchanges
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Executives
John A. Borgeson officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Jason Ehrlich officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth director, 10 percent owner, officer: Chairman, President and CEO 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang officer: See Remarks 2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek director P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016